📅 PUBMED DAILY TRIAGE — 2026-08-19

Window: 2026-08-18T00:00:00Z → 2026-08-19T23:59:59Z (CRDT) Topics scanned: 10 | Articles reviewed: ~110 candidate PMIDs fetched across topics | Candidates evaluated: 23 retained High priority: 7 | Standard: 12 | Low/archive: 4 | Unsolicited finds: 0 Run status: PARTIAL_SUCCESS

🔴🟠 HIGH PRIORITY (8+) — Best Finds by Topic

Hematologic Malignancies (AML, MDS, CLL, MPN, Lymphoma)

42613033 · Danburstotug, an anti-PD-L1 antibody, in R/R extranodal NK/T-cell lymphoma: The phase 2 DISTINKT study · 9/10 · 🟠 NOVEL_TREATMENT → Phase 2 open-label trial (n=23) in R/R ENKTL achieves ORR 78.9%, CR 63.2%, 2-year OS 77.9%—remarkable efficacy in a disease with very limited salvage options; PD-L1 membrane specificity shows biomarker potential.

42613183 · Sequential MRD + KIT variant status in pediatric CBF-AML (Taiwan Pediatric Oncology Group multicenter) · 8/10 · ⬜ NONE → 112-child multicenter study defines actionable sequential MRD log-reduction thresholds combined with KIT D816 variant to stratify risk and guide treatment intensity in pediatric CBF-AML.

42612729 · HCT for blastic plasmacytoid dendritic cell neoplasm: ASTCT clinical practice guidelines · 8/10 · 🟠 NOVEL_TREATMENT → First ASTCT society-level HCT guidelines for BPDCN (GRADE methodology, 17 experts): allo-HCT in CR1, myeloablative conditioning + TBI for fit patients, routine post-HCT intrathecal CNS prophylaxis.

AI/ML in Clinical Diagnostics and Imaging

42612835 · Multimodal AI system for risk-adapted cancer survivorship surveillance: multicenter target trial emulation (n=2,148, 5 centers) · 8/10 · 🟢 NEAR_TERM_IMPLEMENTABLE → Transformer AI integrating MRI + RT dose maps achieves AUC 0.991/0.986 for predicting individualized failure timing in NPC, enabling >90% reduction in surveillance visits for failure-free patients.

Precision Oncology and Genomic Medicine

42612796 · Therapeutic targeting of RAS-mediated resistance in oncogene-driven lung cancer (Ann Oncol, n=590) · 9/10 · 🟠 NOVEL_TREATMENT → RAS alterations drive ~10% of resistance to EGFR/ALK/MET/ROS1/RET inhibitors; combinatorial osimertinib + zoldonrasib (KRAS G12D) or daraxonrasib (pan-RAS) shows marked preclinical synergy, providing clinical trial rationale.

Cardiovascular-Metabolic: GLP-1, SGLT2, Cardiometabolic Risk

42612754 · GLP-1 receptor agonists and risk of diabetic retinopathy in T2DM: systematic review + network meta-analysis of RCTs · 8/10 · 🟢 NEAR_TERM_IMPLEMENTABLE → NMA of GLP-1RA RCTs quantifies comparative diabetic retinopathy risk across agents, directly addressing a clinically important safety signal affecting millions of GLP-1RA-treated patients.

Early Cancer Detection (Liquid Biopsy, ctDNA, cfDNA)

42612958 · Lung cancer risk in cardiac CT patients: identification of a new high-risk population for lung cancer screening (Stanford, n=17,232) · 7/10 · 🔴 EARLY_CANCER_DETECTION → Most cardiac CT recipients who subsequently developed lung cancer did NOT meet USPSTF LCS criteria, identifying this readily accessible population as a major underserved screening opportunity.

Topics with Zero 8+ Articles This Run

• CBC-based diagnostics and ML in hematology: best score 5/10 (42613184)
• Aging, longevity, and population health: best score 6/10 (42613076) — note: partial coverage (4/15 candidates missing)
• Rare diseases with high unmet need: best score 4/10 — partial coverage (7/12 missing)
• Novel therapeutics (standalone): HIGH shared with Hematologic Malignancies topic above

🟢⚪ STANDARD (5–7) — Top by Topic

Hematologic Malignancies

• 42613199 · Safe Integration of RT with Bispecific Antibodies in R/R B-cell Lymphoma · 6/10 · Treatment Innovation
• 42612548 · Cladribine-based salvage therapy in R/R AML: IALG multicenter retrospective · 6/10 · Treatment Innovation

CBC-based Diagnostics / ML in Hematology

• 42613184 · Digital Morphology Analyzer WBC Differentials: Practical EQA Considerations (15-lab multicenter) · 5/10 · Diagnostics

Early Cancer Detection

• 42611962 · Longitudinal CTC Phenotyping using Scalable Deep Learning (SEE-TC; 8.5M cells, 3,386 samples, 6 cancer types) · 7/10 · Early Detection
• 42611507 · AI and Interval Cancers in Screening Mammography · 6/10 · Early Detection
• 42612850 · Decentralization of Liquid Biopsy Use in Thoracic Pathology (perspective review) · 5/10 · Diagnostics

AI/ML in Clinical Diagnostics

• 42612510 · Spatial Immune Microenvironment Features of EGFR Mutation Subtypes in Early-Stage Lung Adenocarcinoma · 6/10 · Genomics/Precision Medicine
• 42612620 · Translating Cellular Aging Clocks into Disease Risk Prediction (Cell Rep Med commentary on 60,000-person proteomics study) · 5/10 · Genomics/Precision Medicine

Precision Oncology

• 42612932 · Resistance to PD-1/PD-L1 Blockade: Mechanisms and Pharmacological Strategies (IUPHAR review) · 6/10 · Drug Development
• 42612560 · Molecular and Immune Profiling of HER2-low/ultra-low/null Male Breast Cancer · 7/10 · Genomics/Precision Medicine 🟡 UNDERSERVED_POPULATION

Cardiovascular-Metabolic

• 42612619 · GLP-1 Receptor Agonists for Alzheimer's Disease: Lessons from Trials (Cell Rep Med review) · 7/10 · Drug Development

Aging / Longevity

• 42613076 · Ageing-associated Regenerative Failure in the Lung: Stem Cell Senescence in IPF (Eur Respir Rev) · 6/10 · Other

💡 UNSOLICITED FINDS

None identified this run. All high-signal articles matched active watchlist topics.

📊 TODAY'S BREAKDOWN

By research category:

• Treatment Innovation: 5
• Early Detection/Diagnostics: 8
• Genomics/Precision Medicine: 5
• Drug Development: 3
• Other/Public Health: 2

By evidence maturity:

• Exploratory: 11
• Validated: 10
• Potentially Practice-Changing: 1 (42612729 ASTCT BPDCN guidelines)
• (Low/archive articles not counted)

By watchlist topic (reviewed / kept / highest score):

By source type: peer_reviewed: 23 | preprint: 0

Topics with zero 8+ articles this run: CBC-based diagnostics + ML, Aging/longevity, Rare diseases (all with partial/full coverage)

🔧 RUN NOTES

Partial coverage (PARTIAL_SUCCESS):

• T5 Precision oncology: 7/15 candidates not fetched (42611325, 42611264, 42611162, 42610618, 42610416, 42610379, 42610315) — best article (42612796, score 9) already captured in first 8 reviewed
• T6 Novel therapeutics: 2/15 candidates not fetched (42612942, 42612716)
• T8 Aging/longevity: 4/15 candidates not fetched (42612095, 42612093, 42612078, 42612032)
• T9 Rare diseases: 7/12 candidates not fetched; no STANDARD articles in reviewed subset
• Sentinel: 5/10 candidates not fetched; no high-signal finds in reviewed subset
• T3 Early cancer detection: 1/15 candidate not fetched (42610891)
• All due to API volume constraints in single run window. Attempt 2 should complete missing coverage.

False positives noted:

• T1 search retrieved wound dressing, ophthalmology, and HIV burden articles via broad "marker" keyword; all scored LOW/irrelevant and excluded from output.
• T3 retrieved nitric oxide RCT protocol (Ann Med) and AMD lncRNA article (JoVE) as false positives; scored LOW.

Notable title-only article:

• 42612808 (ctDNA for Merkel cell carcinoma recurrence, JAAD) had no PubMed abstract at run time; scored LOW (3/10, title-only cap). Potentially high-signal if abstract available — recommend efetch in attempt 2.

Data quality notes:

• 42612620 (Cell Rep Med, aging clocks) is a commentary on a Ding et al. study involving 60,000 individuals; the primary study PMID was not in the CRDT window and should be retrieved separately if desired.
• Aging/longevity humans[MeSH] filter applied per 2026-06-30 tuning (reduced non-human biological noise from 56→61 results, appropriate).

This is attempt 2 of 3. Missing candidate coverage should improve in attempt 2.